The effects of immunosuppressive therapy for immune-mediated inflammatory disease on the risk of age-related macular degeneration.

IF 2.1 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2025-05-12 DOI:10.1097/IAE.0000000000004531

Natan Lishinsky-Fischer, Itay Chowers, Jaime Levy

{"title":"The effects of immunosuppressive therapy for immune-mediated inflammatory disease on the risk of age-related macular degeneration.","authors":"Natan Lishinsky-Fischer, Itay Chowers, Jaime Levy","doi":"10.1097/IAE.0000000000004531","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the effects of immunosuppressive therapy on the development and progression of age-related macular degeneration (AMD) in patients with an immune-mediated inflammatory disease (IMID).Methods: This is a retrospective cohort study. Data were obtained from TriNetX, a global database of electronic medical records. The analysis utilized the largest network in TriNetX, comprised of 171,583,261 patients from 18 countries. Kaplan-Meier analysis was used to estimate the probability of predefined AMD subcategories between patients with IMID who were prescribed an immunosuppressants and patients who were not.Results: After 1:1 propensity score matching, equal-sized cohorts of patients in each group were generated for predefined IMIDs. We found that AMD was more prevalent in patients who received an immunosuppressant for systemic lupus erythematosus (SLE), Crohn's disease, rheumatoid arthritis, sarcoidosis, Sjogren's syndrome, giant cell arteritis and all IMIDs combined.Conclusions: The use of immunosuppressants in patients with some IMIDs appears to be associated with an increased risk of AMD. Further research is warranted in order to fully understand the complex relationship between immunosuppressive therapy and AMD.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004531","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the effects of immunosuppressive therapy on the development and progression of age-related macular degeneration (AMD) in patients with an immune-mediated inflammatory disease (IMID).

Methods: This is a retrospective cohort study. Data were obtained from TriNetX, a global database of electronic medical records. The analysis utilized the largest network in TriNetX, comprised of 171,583,261 patients from 18 countries. Kaplan-Meier analysis was used to estimate the probability of predefined AMD subcategories between patients with IMID who were prescribed an immunosuppressants and patients who were not.

Results: After 1:1 propensity score matching, equal-sized cohorts of patients in each group were generated for predefined IMIDs. We found that AMD was more prevalent in patients who received an immunosuppressant for systemic lupus erythematosus (SLE), Crohn's disease, rheumatoid arthritis, sarcoidosis, Sjogren's syndrome, giant cell arteritis and all IMIDs combined.

Conclusions: The use of immunosuppressants in patients with some IMIDs appears to be associated with an increased risk of AMD. Further research is warranted in order to fully understand the complex relationship between immunosuppressive therapy and AMD.

查看原文本刊更多论文

免疫抑制治疗免疫介导炎性疾病对年龄相关性黄斑变性风险的影响

目的：评价免疫抑制治疗对免疫介导炎性疾病（IMID）患者年龄相关性黄斑变性（AMD）发生和发展的影响。方法：回顾性队列研究。数据来自全球电子医疗记录数据库TriNetX。该分析利用了TriNetX中最大的网络，由来自18个国家的171,583,261名患者组成。Kaplan-Meier分析用于估计IMID患者使用免疫抑制剂和未使用免疫抑制剂的患者之间预定义AMD亚类别的概率。结果：经过1:1的倾向评分匹配后，为预定义的IMIDs生成每组中等大小的患者队列。我们发现，在接受系统性红斑狼疮（SLE）、克罗恩病、类风湿性关节炎、结节病、干燥综合征、巨细胞动脉炎和所有IMIDs联合免疫抑制剂治疗的患者中，AMD更为普遍。结论：在某些IMIDs患者中使用免疫抑制剂似乎与AMD风险增加有关。为了充分了解免疫抑制治疗与AMD之间的复杂关系，需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.